TY - JOUR AU - d'Angelo, Michele AU - Castelli, Vanessa AU - Benedetti, Elisabetta AU - Antonosante, Andrea AU - Catanesi, Mariano AU - Dominguez-Benot, Reyes AU - Pitari, Giuseppina AU - Ippoliti, Rodolfo AU - Cimini, Annamaria PY - 2019 M3 - Review TI - Theranostic Nanomedicine for Malignant Gliomas JO - Frontiers in Bioengineering and Biotechnology UR - https://www.frontiersin.org/articles/10.3389/fbioe.2019.00325 VL - 7 SN - 2296-4185 N2 - Brain tumors mainly originate from glial cells and are classified as gliomas. Malignant gliomas represent an incurable disease; indeed, after surgery and chemotherapy, recurrence appears within a few months, and mortality has remained high in the last decades. This is mainly due to the heterogeneity of malignant gliomas, indicating that a single therapy is not effective for all patients. In this regard, the advent of theranostic nanomedicine, a combination of imaging and therapeutic agents, represents a strategic tool for the management of malignant brain tumors, allowing for the detection of therapies that are specific to the single patient and avoiding overdosing the non-responders. Here, recent theranostic nanomedicine approaches for glioma therapy are described. ER -